Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Jian-Ri
INTerpath-004, NCT06307431: A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004).	Recruiting	2	272	Europe, Canada, US, RoW	V940, mRNA-4157, Pembrolizumab, MK-3475, KEYTRUDA®, Placebo	Merck Sharp & Dohme LLC, ModernaTX, Inc.	Renal Cell Carcinoma	01/28	06/32